Colgate Venture Co.
Executive Summary
Meditech Pharmaceuticals' antiviral agent MTCH-24 will be tested by Colgate for development as a topical skin treatment under an agreement announced April 20. The wholly owned subsidiary of Colgate-Palmolive will have the option to license the agent, which is currently in Phase III clinicals for herpes simplex, influenza A, Epstein-Barr, cytomegalovirus, and respiratory syncytial virus.